Showing results (231-240 of 590) with videos related to
Sort By:
Pageof 59
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.The European Respiratory Journal|August 29, 2024
Pulmonary hypertension associated with lung diseasesOksana A Shlobin, Yochai Adir, Joan A Barbera, et al.Respiratory Research|April 8, 2022
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trialVincent Cottin, Fernando J Martinez, R Gisli Jenkins, et al.European Respiratory Review : an Official Journal of the European Respiratory Society|March 27, 2024
Towards the adoption of quantitative computed tomography in the management of interstitial lung diseaseSimon L F Walsh, Jan De Backer, Helmut Prosch, et al.Annals of the American Thoracic Society|April 10, 2025
Quantitative CT Measures of Lung Fibrosis and Outcomes in the National Lung Screening TrialJennifer M Wang, Swaraj Bose, Susan Murray, et al.ERJ Open Research|December 17, 2024
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosisR Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, et al.Orphanet Journal of Rare Diseases|December 15, 2018
Air travel and incidence of pneumothorax in lymphangioleiomyomatosisCynthia Gonano, Jérôme Pasquier, Cécile Daccord, et al.Respiratory Medicine|November 28, 2016
Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung diseaseJustin M Oldham, Cathryn Lee, Eleanor Valenzi, et al.Respiratory Medicine: X|May 27, 2020
T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survivalCatherine A Bonham, Cara L Hrusch, Kelly M Blaine, et al.ERJ Open Research|July 19, 2023
Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosisJustin M Oldham, Kirk W Johnson, Gesa J Albers, et al.Pageof 59